Compare Manulife Financial Corporation (MFC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Repligen Corporation Common Stock — how do they compare? Manulife Financial Corporation trades at $42.93 (market cap $71.31B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Manulife Financial Corporation is far larger — about 6.4× Repligen Corporation Common Stock's market cap, and Manulife Financial Corporation pays a 3.15% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 120 Days and Repligen Corporation Common Stock for 0 Days on average.
| MFC | RGEN | |
|---|---|---|
Market Cap | $71.31B | $11.14B |
Volume | 1,535,090 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $44.77 | $194.57 |
52-Week Low | $31.64 | $102.87 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $66.58B | $11.02B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.10, up 0.56% today, with a neutral technical signal and bullish moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7% and a P/E of 16.73. Recent news includes a new Chief Marketing Officer appointment and strong institutional investments, such as Bank of America's $145.18 million stake.
The outlook is positive with analyst consensus at Buy (57.14%) and a price target of $34.24, though below the current price. Risks include competitive pressures and debt levels, but earnings beats and dividend payments support stability. Growth is driven by Asia expansion and reinsurance deals, yet valuation premiums may limit near-term upside.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
